Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study

John J. McNeil, Robyn L. Woods, Mark R. Nelson, Anne M. Murray, Christopher M. Reid, Brenda Kirpach, Elsdon Storey, Raj C. Shah, Rory S. Wolfe, Andrew M. Tonkin, Anne B. Newman, Jeff D. Williamson, Jessica E. Lockery, Karen L. Margolis, Michael E. Ernst, Walter P. Abhayaratna, Nigel Stocks, Sharyn M. Fitzgerald, Ruth E. Trevaks, Suzanne G. Orchard & 6 others Lawrence J. Beilin, Geoffrey A. Donnan, Peter Gibbs, Colin I. Johnston, Richard H. Grimm, ASPREE Investigator Group

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.

    Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).

    Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.

    Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

    Original languageEnglish
    Pages (from-to)1586-1593
    Number of pages8
    JournalThe journals of gerontology. Series A, Biological sciences and medical sciences
    Volume72
    Issue number11
    DOIs
    Publication statusPublished - 12 Oct 2017

    Fingerprint

    Aspirin
    Dementia
    Creatinine
    Medical History Taking
    Placebos
    Population
    Minority Groups
    Hand Strength
    Primary Prevention
    Activities of Daily Living
    Dyslipidemias
    Chronic Renal Insufficiency
    Osteoarthritis
    Geriatrics
    Cognition
    Life Style
    Albumins
    Fasting
    Primary Health Care
    Hemoglobins

    Cite this

    McNeil, John J. ; Woods, Robyn L. ; Nelson, Mark R. ; Murray, Anne M. ; Reid, Christopher M. ; Kirpach, Brenda ; Storey, Elsdon ; Shah, Raj C. ; Wolfe, Rory S. ; Tonkin, Andrew M. ; Newman, Anne B. ; Williamson, Jeff D. ; Lockery, Jessica E. ; Margolis, Karen L. ; Ernst, Michael E. ; Abhayaratna, Walter P. ; Stocks, Nigel ; Fitzgerald, Sharyn M. ; Trevaks, Ruth E. ; Orchard, Suzanne G. ; Beilin, Lawrence J. ; Donnan, Geoffrey A. ; Gibbs, Peter ; Johnston, Colin I. ; Grimm, Richard H. ; ASPREE Investigator Group. / Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. In: The journals of gerontology. Series A, Biological sciences and medical sciences. 2017 ; Vol. 72, No. 11. pp. 1586-1593.
    @article{387344ecfed4434f88cee1d4b7d8d263,
    title = "Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study",
    abstract = "Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56{\%} women. Approximately 55{\%} of the U.S. cohort were from minority groups; 9{\%} of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.",
    keywords = "Clinical trial, Dementia, Disability, Primary prevention",
    author = "McNeil, {John J.} and Woods, {Robyn L.} and Nelson, {Mark R.} and Murray, {Anne M.} and Reid, {Christopher M.} and Brenda Kirpach and Elsdon Storey and Shah, {Raj C.} and Wolfe, {Rory S.} and Tonkin, {Andrew M.} and Newman, {Anne B.} and Williamson, {Jeff D.} and Lockery, {Jessica E.} and Margolis, {Karen L.} and Ernst, {Michael E.} and Abhayaratna, {Walter P.} and Nigel Stocks and Fitzgerald, {Sharyn M.} and Trevaks, {Ruth E.} and Orchard, {Suzanne G.} and Beilin, {Lawrence J.} and Donnan, {Geoffrey A.} and Peter Gibbs and Johnston, {Colin I.} and Grimm, {Richard H.} and {ASPREE Investigator Group}",
    year = "2017",
    month = "10",
    day = "12",
    doi = "10.1093/gerona/glw342",
    language = "English",
    volume = "72",
    pages = "1586--1593",
    journal = "Journals Of Gerontology Series A-Biological Sciences And Medical Sciences",
    issn = "1079-5006",
    publisher = "Oxford University Press",
    number = "11",

    }

    McNeil, JJ, Woods, RL, Nelson, MR, Murray, AM, Reid, CM, Kirpach, B, Storey, E, Shah, RC, Wolfe, RS, Tonkin, AM, Newman, AB, Williamson, JD, Lockery, JE, Margolis, KL, Ernst, ME, Abhayaratna, WP, Stocks, N, Fitzgerald, SM, Trevaks, RE, Orchard, SG, Beilin, LJ, Donnan, GA, Gibbs, P, Johnston, CI, Grimm, RH & ASPREE Investigator Group 2017, 'Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study' The journals of gerontology. Series A, Biological sciences and medical sciences, vol. 72, no. 11, pp. 1586-1593. https://doi.org/10.1093/gerona/glw342

    Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. / McNeil, John J.; Woods, Robyn L.; Nelson, Mark R.; Murray, Anne M.; Reid, Christopher M.; Kirpach, Brenda; Storey, Elsdon; Shah, Raj C.; Wolfe, Rory S.; Tonkin, Andrew M.; Newman, Anne B.; Williamson, Jeff D.; Lockery, Jessica E.; Margolis, Karen L.; Ernst, Michael E.; Abhayaratna, Walter P.; Stocks, Nigel; Fitzgerald, Sharyn M.; Trevaks, Ruth E.; Orchard, Suzanne G.; Beilin, Lawrence J.; Donnan, Geoffrey A.; Gibbs, Peter; Johnston, Colin I.; Grimm, Richard H.; ASPREE Investigator Group.

    In: The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 72, No. 11, 12.10.2017, p. 1586-1593.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study

    AU - McNeil, John J.

    AU - Woods, Robyn L.

    AU - Nelson, Mark R.

    AU - Murray, Anne M.

    AU - Reid, Christopher M.

    AU - Kirpach, Brenda

    AU - Storey, Elsdon

    AU - Shah, Raj C.

    AU - Wolfe, Rory S.

    AU - Tonkin, Andrew M.

    AU - Newman, Anne B.

    AU - Williamson, Jeff D.

    AU - Lockery, Jessica E.

    AU - Margolis, Karen L.

    AU - Ernst, Michael E.

    AU - Abhayaratna, Walter P.

    AU - Stocks, Nigel

    AU - Fitzgerald, Sharyn M.

    AU - Trevaks, Ruth E.

    AU - Orchard, Suzanne G.

    AU - Beilin, Lawrence J.

    AU - Donnan, Geoffrey A.

    AU - Gibbs, Peter

    AU - Johnston, Colin I.

    AU - Grimm, Richard H.

    AU - ASPREE Investigator Group

    PY - 2017/10/12

    Y1 - 2017/10/12

    N2 - Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

    AB - Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.

    KW - Clinical trial

    KW - Dementia

    KW - Disability

    KW - Primary prevention

    UR - http://www.scopus.com/inward/record.url?scp=85032643637&partnerID=8YFLogxK

    U2 - 10.1093/gerona/glw342

    DO - 10.1093/gerona/glw342

    M3 - Article

    VL - 72

    SP - 1586

    EP - 1593

    JO - Journals Of Gerontology Series A-Biological Sciences And Medical Sciences

    JF - Journals Of Gerontology Series A-Biological Sciences And Medical Sciences

    SN - 1079-5006

    IS - 11

    ER -